Cabozantinib for Metastatic Triple Negative BrCa

Inclusion Criteria: * Histologically or cytologically confirmed invasive breast cancer with stage IV disease * Primary tumor and/or metastasis must be ER-negative, PR-negative and HER2-negative * May have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer. Must be off treatment for at least 21 days prior to enrollment * Must have discontinued all biologic therapy at least 14 days before enrollment * May have received prior radiation therapy in the early stage or metastatic setting, but must have completed treatment at least 14 days prior to enrollment * Must agree to use medically acceptable methods of contraception * Confirmed availability of formalin-fixed, paraffin-embedded tumor tissue * Able to swallow tablets Exclusion Criteria: * Pregnant or breastfeeding * Received another investigational agent within 14 days prior to enrollment * Received prior c-Met inhibitor * Known brain metastases that are untreated, symptomatic or require therapy to control symptoms * Psychiatric illness or social situation that could limit ability to comply with study requirements * Require concomitant treatment in therapeutic doses with anticoagulants or antiplatelet agents * Diagnosis of another malignancy requiring systemic treatment within the last two years (except non-melanoma skin cancer or in-situ carcinoma of the cervix) * Known to be positive for HIV * Active infection requiring IV antibiotics at Day 1 of cycle 1 * Uncontrolled, significant intercurrent illness * Requires chronic concomitant treatment of a strong CYP3A4 inducer * tumor in contact with, invading or encasing major blood vessels * Have experienced clinically significant gastrointestinal bleeding within 6 months, hemoptysis of more than 0.5 teaspoon of red blood within 3 months or other signs indicative of pulmonary hemorrhage within 3 months of enrollment